Expert Rev Mol Diagn. 2023 Feb 6. doi: 10.1080/14737159.2023.2176223. Online ahead of print.
ABSTRACT
BACKGROUND: : Colorectal cancer (CRC) is the most common cancer and the second leading cause of cancer deaths in Hong Kong. We tested the hypothesis that circulating tumor cell (CTC) analysis by ARB101 antibody could be used as a tool for CRC detection, progression, and therapy response.
RESEARCH DESIGN AND METHODS: : ARB101 antibody was used for investigation of CDH17 expression in formalin-fixed, paraffin-embedded (FFPE) tissue sections and circulating tumor cells (CTCs) of CRC patients.
RESULTS: Using ARB101, highest sensitivity was observed in 98/100 (98%) colorectal cancer tissue compared to 72/100 gastric cancer (72%) and 27/32 pancreatic cancer (84%). Immunoreactivity of CDH17 was significantly higher in distant metastatic (tumor-node-metastasis [TNM] stage IV) than non-distant metastatic (TNM stage I to III) colorectal cancer. ARB101 antibody also manifested the higher sensitivity than c-erbB2 (8%) and epidermal growth factor receptor (EGFR)-targeting antibodies (37%) with the significance (p < 0.0001). ARB101 positive CTCs were detected in 64/83 (77%) TNM stage I to IV colorectal cancer patients. Detailed analysis showed that ARB101 positive CTCs (threshold ⩾1) were identified in 17/25 stage I (68%), 14/21 stage II (67%), 18/21 stage III (86%) and 15/16 stage IV (94%) colorectal cancer patients. Furthermore, ARB101 positive CTCs were detected in TNM stage I to III colorectal cancer patients before and after surgical operation. The difference of ARB101 positive CTCs between those 2 groups of matched patient samples are statistically significant (p < 0.0001).
CONCLUSIONS: CTC detection by ARB101 antibody could serve as a potential non-invasive approach for CRC detection, progression, and monitoring treatment response of colorectal cancers.
PMID:36744385 | DOI:10.1080/14737159.2023.2176223
